pharmaphorum Podcast

• Prevention for a healthier, more productive society

  In a new pharmaphorum podcast, recorded during Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh spoke with David Gillen, chief medical officer at Norgine, about the role of prevention in the future of healthcare. Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The Prevention Revolution in Your Healthcare’, exploring the key takeaways and exciting possibilities from the panel discussion. Prevention is increasingly seen as contributing to a healthier and more productive society. But, as healthcare resources are stretched and medical science is accelerating, the question remains: how do we make prevention a reality? Encouragingly, healthcare systems are increasingly seeing the health, social, and economic benefits of prevention when it is delivered in an evidence-based way. You can listen to episode 172a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  15:13
• Safeguarding the pharmaceutical supply chain

  As we hear of the volcanic and seismic activity taking place in Iceland this week, pharmaphorum turns back to a conversation with Dean Alms, CPO of Aravo, on how extreme weather highlights the need to make adequate supply chain preparations for the seasons in which the planet pulls out all the stops with the worst of its natural disasters. Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency protocols and drug reserves to be in place in the worst-case scenarios, and permits plants to return to full operation as speedily as possible. And this is where Aravo, a third-party management software solutions company, comes in, operating at three macro levels: life cycle management, the due diligence process, and providing unified visibility into all this information. Alms talks through the different scenarios and ways of approach to best safeguard the pharmaceutical supply chain, and explains what should be top of mind for chief risk officers when each extreme weather season arrives. You can listen to episode 171a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  13:37
• For the continuum of mental health we need a whole system, holistic 'healthspan'

  If we don’t address the mental health of young people, that mental health challenge will advance into the adult population of tomorrow. What can be done to address the issue, though? At Anthropy 2025: Rebooting Britain, web editor Nicole Raleigh sat down with Dr Sebastian Vaughn, CEO of Phytome Life Sciences, for an en plein air and explorative conversation around the topic, live onsite at The Eden Project in Cornwall, following the Adelphi sponsored panel, ‘Revolutionary Thinking for Mental Health’, also with: Charlotte Baldwin, Mental Health UK; Dr Lauren Waterman, NHS; Sarah Hughes, MIND; and Dr Sri Kalidindi CBE, klip Global Ltd; and Lloyd Morgan, Adelphi Group, as moderator. Action in the real world resultant from discussions like those held at Anthropy is what is, of course, critical. We are all agents of change. Mental health is not a binary issue, says Vaughn, but rather a continuum of a life-long management process. However, the healthcare system alone is not the only point of delivery, and community-based solutions need to be put in place, too. Indeed, it is this system shift to collaborative efforts that will be key in changing the recent high tide of mental health diagnoses, including training teachers and even parents in the skills necessary to provide support for young people with mental health issues. Also exploring the increase in diagnosis, the lessening of stigma attached to mental health, and potential reasons there – Vaughn posits that ‘healthspan’, as opposed to ‘healthcare’, should be considered. Arguing against associating addressing mental health with putting people back to work and mere consideration of productivity amelioration, instead we should be asking what helps us thrive as human beings, says Vaughn. We need, simply, to live better, and live well – such strategies currently being implemented in communities such as those in Manchester. But, of course, young people themselves need to be offered a place at the table to make the changes they need for their own mental health; systemic change of the culture around mental health. And novel, holistic approaches that can be scaled – such as those being explored at Phytome – could be part of the necessary shift. You can listen to episode 170a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  35:49
• IRA updates and making sense of the chaos in Washington, with Alice Valder Curran

  Last year, Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy expert in Washington, D.C. joined host Jonah Comstock on the pharmaphorum podcast to talk about the intended and unintended consequences of the drug pricing negotiation provisions in the Inflation Reduction Act. On today’s episode, Curran joins us once again for an update on the IRA, looking at the second batch of drugs announced in January, recent messaging from the Centers for Medicare and Medicaid Services and what it might communicate about their thinking, and more analysis of IRA’s consequences, including a recent study on the impact of the IRA on early stage investment. She also talks about the possibility that, because of perverse incentives for pharmacy benefit managers, patient access to medications negotiated under the IRA could actually get worse. And she looks ahead to the third round of negotiations, which will see Part D drugs, including Keytruda, become eligible. While the IRA was the main focus of discussion, Curran and Comstock discuss a lot more about the current chaotic environment in DC, including the potential impact of layoffs on the functioning of agencies like CMS and FDA, the outlook for the possibility of IRA reform under the Trump administration, and the recent dispatch from Secretary of Health and Human Services Robert F. Kennedy indicating a change in policy around notice and comment rulemaking.  Things are happening fast in the United States government and the ripples could have big effects for the pharma industry. Tune in for the low-down from an expert insider. 

  --------  

  38:29
• GenAI and the revolution of drug development

  It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life sciences sector can speed up the process, wiping months or even years off that average. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Bryan Hill, life sciences chief technology officer at Cognizant, in a conversation on how generative AI is revolutionising life sciences and drug development. Though it might seem an obvious path, not all life sciences companies are jumping on the bandwagon to adopt GenAI. Instead, many are taking a wait-and-see approach, staying put until the course forward is clearer to incorporate the technology. You can listen to episode 169a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

  --------  

  11:05

Altri podcast di Scienze

Podcast di tendenza in Scienze

Su pharmaphorum Podcast